Literature DB >> 31937570

Patterns of long-term ADHD medication use in Australian children.

Daryl Efron1,2, Melissa Mulraney3,4, Emma Sciberras5,6, Harriet Hiscock5,7, Stephen Hearps8, David Coghill4,9.   

Abstract

OBJECTIVE: Adherence to attention-deficit/hyperactivity disorder (ADHD) medication treatment is often suboptimal. This can compromise patient outcomes. We aimed to describe the patterns of ADHD medication use in Australian children, and characteristics associated with patterns of use.
DESIGN: Dispensing data were analysed for all redeemed prescriptions of methylphenidate, dexamphetamine and atomoxetine between May 2002 and March 2015 from waves 1 to 6 of the Longitudinal Study of Australian Children (n=4634, age 4-5 years at wave 1). Medication coverage was defined as the proportion of time between the first and the last redeemed prescriptions in which the child was taking medication. Associations between predictor variables (child sex, ADHD symptom severity, age at first prescription, family socioeconomic status (SES), single parent status, parent education and parent mental health) and medication coverage were examined using regression analyses.
RESULTS: 166 (3.6%) children had ever redeemed a prescription for an ADHD medication. Boys had higher odds of having taken ADHD medication than girls (OR=3.9; 95% CI 2.7 to 5.7). The mean medication coverage was 59.8%. Medication coverage was lower in children from families of lower SES (β=4.0; 95% CI 0.2 to 7.8, p=0.04). Medication coverage was relatively high in the first year of prescription, then decreased progressively, only increasing again after 5 or 6 years of treatment.
CONCLUSIONS: Children with ADHD from socially disadvantaged families were less likely to receive medication consistently. Prescribers need to continue to support families over many years to ensure medication is used consistently for children with ADHD. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adherence; attention-deficit/hyperactivity disorder; medication

Year:  2020        PMID: 31937570     DOI: 10.1136/archdischild-2019-317997

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Evidence That Methylphenidate Treatment Evokes Anxiety-Like Behavior Through Glucose Hypometabolism and Disruption of the Orbitofrontal Cortex Metabolic Networks.

Authors:  Felipe Schmitz; Josiane S Silveira; Gianina T Venturin; Samuel Greggio; Guilherme Schu; Eduardo R Zimmer; Jaderson Costa Da Costa; Angela T S Wyse
Journal:  Neurotox Res       Date:  2021-11-19       Impact factor: 3.911

2.  Child, parent, and family mental health and functioning in Australia during COVID-19: comparison to pre-pandemic data.

Authors:  E M Westrupp; C Bennett; T Berkowitz; G J Youssef; J W Toumbourou; R Tucker; F J Andrews; S Evans; S J Teague; G C Karantzas; G M Melvin; C Olsson; J A Macdonald; C J Greenwood; A Mikocka-Walus; D Hutchinson; M Fuller-Tyszkiewicz; M A Stokes; L Olive; A G Wood; J A McGillivray; E Sciberras
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-08-21       Impact factor: 5.349

Review 3.  New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.

Authors:  David J Heal; Jane Gosden; Sharon L Smith
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Utilization of Drugs for Attention-Deficit Hyperactivity Disorder Among Young Patients in China, 2010-2019.

Authors:  Zhiliang Wang; Xiaoyan Wu; Zhenwei Yu; Lingyan Yu
Journal:  Front Psychiatry       Date:  2022-02-09       Impact factor: 4.157

5.  Psychotropic medication prescribing trends in a developmental-behavioural clinic during the COVID-19 pandemic.

Authors:  Jun J Ong; Gehan Roberts
Journal:  J Paediatr Child Health       Date:  2022-04-18       Impact factor: 1.929

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.